{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:21:31Z","timestamp":1792794091609,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Netherlands Organization for Health Research and Developmen","award":["113202001"],"award-info":[{"award-number":["113202001"]}],"id":[{"id":"https:\/\/ror.org\/01yaj9a77","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI213008"],"award-info":[{"award-number":["WI213008"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TIMID","award":["LSHM18057-SGF"],"award-info":[{"award-number":["LSHM18057-SGF"]}]},{"name":"Life Sciences & Health"},{"name":"Samenwerkende Gezondheidsfondsen"},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite its efficacy, rational guidance for starting\/stopping first-line biologic treatment in individual paediatric Crohn\u2019s disease [CD] patients is needed. We assessed how serum immune profiles before and after first-line infliximab [FL-IFX] or conventional [CONV] induction therapy associate with disease remission at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pre- [n\u2005=\u200586], and 10\u201314-week post-treatment [n\u2005=\u200584] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [n\u2005=\u200548; five 5-mg\/kg infusions over 22 weeks] or CONV [n\u2005=\u200543; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. The relative concentrations of 92 inflammatory proteins were determined with Olink Proteomics; fold changes [FC] with |log2FC| &amp;gt; 0.5 after false discovery rate adjustment were considered significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FL-IFX modulated a larger number of inflammatory proteins and induced stronger suppression than CONV; 18\/30 proteins modulated by FL-IFX were not regulated by CONV. Hierarchical clustering based on IFX-modulated proteins at baseline revealed two clusters of patients: CD-hi patients had significantly higher concentrations of 23\/30 IFX-modulated proteins [including oncostatin-M, TNFSF14, HGF and TGF-\u03b1], and higher clinical disease activity, C-reactive protein and blood neutrophils at baseline than CD-lo patients. Only 24% of CD-hi FL-IFX-treated patients maintained remission without escalation at week 52 vs 58% of CD-lo FL-IFX-treated patients. Similarly, 6% of CD-hi CONV-treated patients achieved remission vs 20% of CONV-treated CD-lo patients. Clustering based on immune profiles post-induction therapy did not relate to remission at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FL-IFX leads to stronger reductions and modulates more immune proteins than CONV. Stratification on pre-treatment profiles of IFX-modulated proteins directly relates to maintenance of remission without treatment escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT02517684.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad049","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T20:11:32Z","timestamp":1678997492000},"page":"1262-1277","source":"Crossref","is-referenced-by-count":23,"title":["Serum Immune Profiling in Paediatric Crohn\u2019s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments"],"prefix":"10.1093","volume":"17","author":[{"given":"Maria M E","family":"Jongsma","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea M M","family":"Costes","sequence":"additional","affiliation":[{"name":"Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Tindemans","sequence":"additional","affiliation":[{"name":"Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinus A","family":"Cozijnsen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolien (H) C","family":"Raatgreep","sequence":"additional","affiliation":[{"name":"Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Pieterson","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology & Clinical Bioinformatics, Erasmus University Medical Center\/Erasmus MC Cancer Institute , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C","family":"Escher","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke N","family":"Samsom","sequence":"additional","affiliation":[{"name":"Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus University Medical Center\/Sophia Children\u2019s Hospital , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,19]]},"reference":[{"key":"2023082114501837600_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2023082114501837600_CIT0002","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2249.1995.tb03836.x","article-title":"Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)","volume":"102","author":"Duchmann","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2023082114501837600_CIT0003","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cells9010110","article-title":"Dissecting the heterogeneity in t-cell mediated inflammation in IBD","volume":"9","author":"Tindemans","year":"2020","journal-title":"Cells"},{"key":"2023082114501837600_CIT0004","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn\u2019s disease complicated by strictures: A systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"2023082114501837600_CIT0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/ecco-jcc\/jjz111","article-title":"Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn\u2019s disease: Results from the Porto Group Growth Study","volume":"14","author":"Levine","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0006","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1136\/gutjnl-2017-314519","article-title":"Early intervention in Crohn\u2019s disease: Towards disease modification trials","volume":"66","author":"Danese","year":"2017","journal-title":"Gut"},{"key":"2023082114501837600_CIT0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5223\/pghn.2018.21.1.1","article-title":"Early biologic treatment in pediatric Crohn\u2019s disease: Catching the therapeutic window of opportunity in early disease by treat-to-target","volume":"21","author":"Kang","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"2023082114501837600_CIT0008","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00365521.2021.1880626","article-title":"Early infliximab in Crohn\u2019s is associated with decreased intestinal surgery and similar health care costs","volume":"56","author":"Singh","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"2023082114501837600_CIT0009","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/MIB.0000000000000679","article-title":"Anti-TNF therapy within 2 years of Crohn\u2019s disease diagnosis improves patient outcomes: A retrospective cohort study","volume":"22","author":"Ma","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2023082114501837600_CIT0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/gut.2010.217117","article-title":"Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNF\u03b1 treatment","volume":"60","author":"Veltkamp","year":"2011","journal-title":"Gut"},{"key":"2023082114501837600_CIT0011","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2023082114501837600_CIT0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"key":"2023082114501837600_CIT0013","article-title":"The medical management of paediatric Crohn\u2019s disease: An ECCO-ESPGHAN guideline update","author":"van Rheenen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0014","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S2468-1253(19)30340-1","article-title":"Personalised medicine in Crohn\u2019s disease","volume":"5","author":"Noor","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023082114501837600_CIT0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: The SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"2023082114501837600_CIT0016","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0016-5085(98)70476-7","article-title":"Early lesions of recurrent Crohn\u2019s disease caused by infusion of intestinal contents in excluded ileum","volume":"114","author":"D\u2019Haens","year":"1998","journal-title":"Gastroenterology"},{"key":"2023082114501837600_CIT0017","article-title":"Designing clinical trials in paediatric inflammatory bowel diseases: A PIBDNET commentary","author":"Turner","year":"2019","journal-title":"Gut"},{"key":"2023082114501837600_CIT0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0019","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/ecco-jcc\/jjab009","article-title":"Can serum proteomic profiling annunciate individual disease progression in newly diagnosed inflammatory bowel disease patients","volume":"15","author":"Atreya","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0020","article-title":"Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease","author":"Kalla","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0021","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/apt.16136","article-title":"Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn\u2019s disease","volume":"53","author":"Ungaro","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2023082114501837600_CIT0022","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/bmjgast-2016-000123","article-title":"Top-down infliximab study in kids with Crohn\u2019s disease (TISKids): An international multicentre randomised controlled trial","volume":"3","author":"Cozijnsen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"2023082114501837600_CIT0023","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ibd.21649","article-title":"Mathematical weighting of the pediatric Crohn\u2019s disease activity index [PCDAI] and comparison with its other short versions","volume":"18","author":"Turner","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2023082114501837600_CIT0025","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.4049\/jimmunol.174.12.8173","article-title":"The critical role of light in promoting intestinal inflammation and Crohn\u2019s disease","volume":"174","author":"Wang","year":"2005","journal-title":"J Immunol"},{"key":"2023082114501837600_CIT0026","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4049\/jimmunol.0804169","article-title":"Expression of IL-24, an activator of the JAK1\/STAT3\/SOCS3 cascade, is enhanced in inflammatory bowel disease","volume":"183","author":"Andoh","year":"2009","journal-title":"J Immunol"},{"key":"2023082114501837600_CIT0027","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ecco-jcc\/jjy014","article-title":"Long-term outcome of early combined immunosuppression versus conventional management in newly diagnosed Crohn\u2019s disease","volume":"12","author":"Hoekman","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0028","article-title":"Infliximab at diagnosis: Moving towards personalisation in paediatric inflammatory bowel disease","author":"Ashton","year":"2021","journal-title":"Gut"},{"key":"2023082114501837600_CIT0029","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"2023082114501837600_CIT0030","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"2023082114501837600_CIT0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102529","article-title":"A review on the use of anti-tnf in children and adolescents with inflammatory bowel disease","volume":"20","author":"Aardoom","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023082114501837600_CIT0032","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: Results from the coin study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"2023082114501837600_CIT0033","article-title":"Discovery of biomarker candidates associated with the risk of short-term and mid\/long-term relapse after infliximab withdrawal in Crohn\u2019s patients: a proteomics-based study","author":"Pierre","year":"2020","journal-title":"Gut"},{"key":"2023082114501837600_CIT0034","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2017.09.061","article-title":"Outcomes 7 years after infliximab withdrawal for patients with Crohn\u2019s disease in sustained remission","volume":"16","author":"Reenaers","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023082114501837600_CIT0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S2468-1253(19)30186-4","article-title":"De-escalation of immunomodulator and biological therapy in inflammatory bowel disease","volume":"5","author":"Chapman","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023082114501837600_CIT0036","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"key":"2023082114501837600_CIT0037","doi-asserted-by":"crossref","first-page":"EVIDoa2200061","DOI":"10.1056\/EVIDoa2200061","article-title":"Discontinuation of infliximab therapy in patients with Crohn\u2019s disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evidence"},{"key":"2023082114501837600_CIT0038","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/apt.15016","article-title":"Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn\u2019s disease","volume":"48","author":"Ziv-Baran","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2023082114501837600_CIT0039","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab075.038","article-title":"The effect of phenotype and genotype on the plasma proteome in patients with inflammatory bowel disease","author":"Bourgonje","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0040","article-title":"A role for CXCR3 ligands as biomarkers of post-operative Crohn\u2019s disease recurrence","author":"Walshe","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023082114501837600_CIT0041","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2021.07.026","article-title":"Systemic inflammation in preclinical ulcerative colitis","volume":"161","author":"Bergemalm","year":"2021","journal-title":"Gastroenterology"},{"key":"2023082114501837600_CIT0042","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V93.4.1413","article-title":"Oncostatin M production and regulation by human polymorphonuclear neutrophils","volume":"93","author":"Grenier","year":"1999","journal-title":"Blood"},{"key":"2023082114501837600_CIT0043","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"2023082114501837600_CIT0044","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/ibd\/izab032","article-title":"Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease","volume":"27","author":"Verstockt","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2023082114501837600_CIT0045","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2014.02.010","article-title":"The tumor necrosis factor family member TNFSF14 [LIGHT] is required for resolution of intestinal inflammation in mice","volume":"146","author":"Krause","year":"2014","journal-title":"Gastroenterology"},{"key":"2023082114501837600_CIT0046","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.4049\/jimmunol.164.8.4105","article-title":"LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response","volume":"164","author":"Tamada","year":"2000","journal-title":"J Immunol"},{"key":"2023082114501837600_CIT0047","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.4049\/jimmunol.167.11.6330","article-title":"Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction","volume":"167","author":"Shaikh","year":"2001","journal-title":"J Immunol"},{"key":"2023082114501837600_CIT0048","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI200113827","article-title":"The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT","volume":"108","author":"Wang","year":"2001","journal-title":"J Clin Invest"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad049\/50062777\/jjad049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/8\/1262\/51193531\/jjad049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/8\/1262\/51193531\/jjad049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T21:49:21Z","timestamp":1702072161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/8\/1262\/7080700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,19]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,19]]},"published-print":{"date-parts":[[2023,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad049","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,19]]}}}